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Abstract The concentration of carbonmonoxide (CO) in exhaled air is increased inpatientswith asthma, bronchiec-
tasis andupper respiratory tract viral infections.However there is no information aboutthe level of COinpatientswith
lower respiratory tract infection.We studied a group of 35 patients (22 males) aged 4573 (SEM) years with cough pro-
ductive ofpurulentphlegmandpyrexia in ageneralpractice setting.Allwerenon-smokersorex-smokers andnonehada
previous history of respiratory problems or diabetes.Wemeasured CO level in exhaled air before and after a course of
antibiotics.Therapywas deemed successfulwhenpatient no longer complained of coughproductive of purulentphlegm.
Twenty-eight of 35 patients had elevated CO level at their initial visit.Twenty-two out of 35 patients reported clinical
improvement after antibiotic treatment and this was associated with a fall in exhaled CO level from 5?270?5 ppm to
2?370?3 ppm (Po0?0001).We suggest that simple COmeasurements in exhaled air can detect the in£ammatory pro-
cesswithinthe airways causedbyinfection andthat a repeatmeasurementcanbeusedto assess thenature ofin£amma-
tion.r2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1196, available online at http://www.idealibrary.comon
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Carbon monoxide (CO) is produced in many tissues of
the body by the enzyme heme oxygenase-1 (HO-1),
which may be induced by in£ammation and oxidative
stress (1). Since HO-1has been found in alveolar macro-
phages (2) and vascular endothelium (3) there have been
suggestions that the level of exhaled CO may be a mar-
ker of in£ammation and oxidative stress in airways.
In£ammation and oxidative stress may induce HO-1and
the concentration ofCO in exhaled air and thereforeCO
levels are increased in patientswith asthma and other in-
£ammatory lung diseases (4^8). Infection may increase
HO-1 expression and a recent study showed increased
CO levels in subjects with symptoms of upper respira-
tory tract viral infections (6). There is no information
about the levels of CO levels in patients with symptoms
of lower respiratory tract infections. Measurement of
exhaled CO is simple and may provide a non-invasive
means of monitoring respiratory infections in a general
practice setting.Received 3 May 2001, accepted in revised form 6 August 2001and
published online 22 October 2001.
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of Thoracic Medicine,National Heart and Lung Institute,Dovehouse
Street, London SW3 6LY,U.K.Fax: 0207 3515675; E-mail:
p.j.barnes@ic.ac.ukMETHODS
The study population consisted of 35 patients (22 males)
aged 4573 (SEM) years, attending a general practice clinic
with symptoms of lower respiratory tract infection. All
the subjects had a history of cough productive of puru-
lent sputum andpyrexia for at least 3 days.Most of them
were non-smokers and only ¢ve were ex-smokers,
having smoked 572 pack-years.None of themwere pas-
sive smokers. They had no previous history of chest
problems or diabetes and were not receiving any long-
term medication. All subjects had their smoking status
con¢rmed twice by urine dipstick testing for the pre-
sence of nicotine and/or its metabolites (NicCheckTest
strips, Dynagen Inc, Cambridge, MA,U.S.A.). After phy-
sical examination and completing a medical question-
naire we measured peak expiratory £ow (PEF) and CO
in exhaled air. Ambient CO level wasmeasured and was
subtracted from the value obtained.However according
to our previous study ambient air CO concentrations at
levels 0^2ppm do not a¡ect exhaled CO.
Subsequently, all patients were given a course of a
wide spectrum antibiotic (amoxycillin 500mg tds or
erythromycin 500mg qds if they were allergic to
penicillin) and asked to come back after 7 days for
repetition of the tests. Therapy was deemed successful
when the patient no longer complained of cough
1004 RESPIRATORYMEDICINEproductive of sputum. Exhaled CO was measured by
portable Bedfont E50 analyser (Bedfont Technical
Instruments Ltd., Sittigbourne, Kent,U.K.) using a single
slow exhalation (9).
The ethics committee approved the study.
Statistical analysis
Data are given as means7SEM. Comparison between
groups was made by a Student’s t-test. Signi¢cance was
de¢ned as Po0?05.
RESULTS
Physical examination revealedpyrexia4381C, but there
was no other abnormalities detected. All patients had
PEF o80% of normal, which did not change after the
treatment with antibiotic. During the ¢rst visit patients
produced sputum samples, which con¢rmed purulent
appearance.
Twenty-eight of 35 patients had elevated CO level at
their initial visit compared to 37 normal non-smoking
subjects (normal level 2?970?2ppm) (10). Twenty-nine
patients were treated with amoxycillin and six with
erythromycin.
Twenty-two out of 35 patients reported clinical
improvement and this coincided with a fall of exhaled
CO level from 5?270?5ppm to 2?370?3ppm
[Po0?0001; Fig. 1(a)]. In the remaining 13 patients who
did not improve, there were no signi¢cant changes in
exhaled CO levels, with CO level of 3?871?5ppm at the
initial visit and 3?871?4ppm after treatment with
antibiotic [P40?05; Fig. 1(b)]. Since there was a bigFIG. 1. Exhaled carbon monoxide (CO) before and after antibiot
respiratory tract infection. (a) Patientswith clinical improvement; (bdi¡erence between the number of patients who were
treated either with amoxycillin or erythromycin, it was
not possible to make any comparison between
exhaled CO level responses in each of the group. Seven
patients had ‘normal’ exhaled CO levels (o3ppm) at
initial visit. Three of those patients had clinical
improvement after the treatment with antibiotic.
However, in the other four patients therewas no clinical
improvement.
DISCUSSION
Our study showed that themajorityofpatientswith clin-
ical symptoms of lower respiratory tract infection had
elevated exhaled CO levels. The clinical improvement
after the treatmentwith antibiotics was associatedwith
a reduction of exhaled CO.However, in13 patients there
was no clinical improvement after the treatment with
antibiotic. In this group of patients the exhaledCO levels
were lower, but statistically not signi¢cant, compared to
the group who did respond. The reason for that could
be that either they were treated with inappropriate
antibiotic or they were su¡ering from a viral infection.
In the other similar study there was a signi¢cant reduc-
tion in exhaled CO level after the upper respiratory
tract infection, but the observation period was much
longer than in our study (6). Seven patients had ‘normal’
initial measurement of exhaled CO level (below 3ppm).
However our ‘normal’ values di¡ered from the other,
similar study. If we accepted normal values our patients
would have abnormal measurements. It is therefore
necessary to establish and unify ‘normal’ values for the
measurement of exhaled CO.ic treatment in two groups of patients with symptoms of lower
) patientswithoutclinical improvement.
EXHALEDCOINPATIENTSWITHLOWERRESPIRATORY TRACT INFECTION 1005Although the exact cellular source of exhaled CO is
not known, its elevation may re£ect presence of i
n£ammation and/or oxidative stress within airways (11).
An elevation in exhaled CO has been reported in
patients with mild and acute asthma with a subsequent
fall after the treatment with inhaled corticosteroids (4).
CO levels were elevated in patients with asthma
following allergen challenge (12). More recently, an
elevation of exhaled CO has been found in patients with
upper respiratory tract infection, which subsequently
fell after the recovery (6). Some of the patients in this
study also had symptoms of lower respiratory tract in-
fection.
Similarly, nitric oxide (NO), another marker of
airways in£ammation, has been found to be elevated in
subjects with upper respiratory tract infection. NO
level subsequently fell after the recovery period (13).
Also, an elevated NO has been found in patients with
asthma, which fell on treatment with inhaled steroids
(14^16).
Our study showed an elevation of exhaled CO level in
majority of patients with lower respiratory tract
infection, which subsequently fell after the treatment
with antibiotics. Bacterial infection may induce
production of heme oxygenase, which has been shown
to participate in resolution of in£ammation in animals
(17).Therefore, increased levels of exhaled CO in lower
respiratory tract infection may re£ect increased
in£ammation and oxidative stress in airways and could
be a single, non-invasive tool for monitoring treatment
with antibiotic. We have previously demonstrated an
elevation of exhaled CO in patients with bronchiectasis
(7) and cystic ¢brosis (8), indicating that di¡erent types
of in£ammation may increase exhaled CO and that this
measurement is not speci¢c for any particular
in£ammatory disease of airways. Repeated
measurements after treatment with either an inhaled
corticosteroid (4,5) or an antibiotic provides information
about the control of in£ammation.Our study con¢rmed
an elevation of exhaled CO in patientswith symptoms of
lower respiratory tract infection. The levels of CO
subsequently fell after the treatment with antibiotic,
which coincidedwith clinical improvement.
We suggest that simple CO measurement in exhaled
air can detect increased in£ammatory process within
the airways, which has been caused by infection. The
return of CO levels to normal after the treatment may
be related to the reduction in in£ammation. Elevatedexhaled CO levels may provide an early warning signal
for an acute infection episode.
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